Health Information Search Results
Peer Reviewed Scientific Research Reports.
|<< Prev 20 ||Showing 1 to 20 of 5,117 Matches||Next 20 >>|
1. Blocking interleukin-1ß in acute and chronic autoinflammatory diseases.
Match Strength: 3.717
An expanding spectrum of acute and chronic inflammatory diseases is considered 'autoinflammatory' diseases. This review considers autoinflammatory diseases as being distinct from 'autoimmune' diseases. Autoimmune diseases are associated with dysfunctional T cells and treated with 'biologicals', including antitumour necrosis factora, CTLA-Ig, anti-IL-12/23, anti-CD20, anti-IL-17 and anti-IL-6 receptor. In contrast, autoinflammatory diseases are uniquely attributed to a dysfunctional monocyte caspase 1 activity and secretion of IL-1ß; indeed, blocking IL-1ß results in a rapid and sustained ... Read More »
» Published in J Intern Med. 2011 Jan;269(1):16-28. doi: 10.1111/j.1365-2796.2010.02313.x.
2. Autoimmune bullous diseases: diagnosis and management.
Match Strength: 3.109
Autoimmune bullous diseases are a heterogenous group of diseases characterized by cutaneous and mucosal vesicles and bullae. Diagnosis is based on a combination of clinical, histopathological, and immunofluorescence findings. Current treatment, including vigilant wound care, significantly reduces disease morbidity and mortality ... Read More »
» Published in Dermatol Nurs. 2006 Feb;18(1):20-5.
3. Inflammatory molecules: a target for treatment of systemic autoimmune diseases.
Match Strength: 3.039
Inflammation is a process to protect the host against infection and danger signals. However, many pathologic conditions, including autoimmune diseases, are sustained by perpetual activation of the inflammatory process. In the past few years our knowledge about the molecular basis of inflammation have been uncovered and now much is known about the primary role of pro-inflammatory cytokines such as IL-1 and TNF. In the early '90s, anti-cytokine therapies started and confirmed the primary role of TNF in autoimmune diseases, such as rheumatoid arthritis, Crohn's Disease and psoriasis. Increasing ... Read More »
» Published in Autoimmun Rev. 2007 Nov;7(1):1-7. Epub 2007 Mar 26.
4. Canadian Association of Neurosciences Review: polyglutamine expansion neurodegenerative diseases.
Match Strength: 3.031
Since the early 1990s, DNA triplet repeat expansions have been found to be the cause in an ever increasing number of genetic neurologic diseases. A subset of this large family of genetic diseases has the expansion of a CAG DNA triplet in the open reading frame of a coding exon. The result of this DNA expansion is the expression of expanded glutamine amino acid repeat tracts in the affected proteins, leading to the term, Polyglutamine Diseases, which is applied to this sub-family of diseases. To date, nine distinct genes are known to be linked to polyglutamine diseases, including Huntington's ... Read More »
» Published in Can J Neurol Sci. 2006 Aug;33(3):278-91.
5. 10H-Phenothiazines: a new class of enzyme inhibitors for inflammatory diseases.
Match Strength: 3.017
The phenothiazine nucleus is known for their inhibitory activity towards the regulatory enzymes that are contributing to diseases such as asthma, autoimmune diseases including allergic rheumatoid and encephalomyelitis. In this study a number of substituted phenothiazines were synthesized and screened for their biological activity against the regulatory enzymes involved in inflammatory diseases. Our results show that the newly synthesized compounds 4a-c and 5a-c exhibited promising target specific enzyme inhibition against phosphodiesterase, prostaglandin dehydrogenase and superoxide dismutase ... Read More »
» Published in Eur J Med Chem. 2009 Jan;44(1):197-202. Epub 2008 Mar 7.
6. ANCA in the diagnosis of neutrophil-mediated inflammation.
Match Strength: 2.979
Inconsistencies in ANCA (anti-neutrophil cytoplasm autoantibodies) and other NSA (neutrophil-specific autoantibodies) terminology frequently cause incorrect indications, choices, applications and interpretations of ANCA diagnostics in routine practice, except for ANCA-associated vasculitis. A review of the current knowledge and the authors' personal experiences based on routine assessments of ANCA and other NSA are documented and presented. A better understanding of the principles and mechanisms of ANCA and other NSA responses and determination, as well as unification of their terminology ... Read More »
» Published in Autoimmun Rev. 2010 Nov 20.
7. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.
Match Strength: 2.974
More than any other cytokine family, the interleukin-1 (IL-1) family of ligands and receptors is associated with acute and chronic inflammation. The cytosolic segment of each member of the IL-1 receptor family contains the Toll IL-1 Receptor (TIR) domain. This domain is also present in each member of the Toll-like Receptors (TLR), the receptors that respond to the wide spectrum of microbial products and viruses. Since TIR is the functional domain of both receptor families, responses to IL-1 are fundamental to the innate immunity. Of the 11 members of the IL-1 family, IL-1ß has emerged as a ... Read More »
» Published in Blood. 2011 Feb 8.
8. Leukocyte navigation mechanisms as targets in airway diseases.
Match Strength: 2.923
Respiratory diseases, including asthma and chronic obstructive pulmonary disease, are among the most significant diseases in terms of their disabling effects and healthcare burden. A characteristic feature of almost all respiratory diseases is the accumulation and activation of inflammatory leukocytes in the lung or airway. Recent advances in the understanding of the molecules and intracellular signalling events controlling these processes are now translating to new therapeutic entities. In this article, the process of leukocyte accumulation is summarized, together with the preclinical and ... Read More »
» Published in Drug Discov Today. 2006 Oct;11(19-20):866-79. Epub 2006 Sep 7.
9. An update on autoinflammatory diseases. New concepts for new and old diseases.
Match Strength: 2.920
The discovery of MEFV as the susceptibility gene for autosomal recessive Familial Mediterranean Fever (FMF) in 1997 represents the beginning of the new era of the monogenic autoinflammatory diseases. During the last decade, the increasing knowledge on the pathogenic mechanisms related to a number of diseases associated to mutations of genes associated to autoinflammatory diseases had a terrific impact on the understanding of pivotal mechanisms regulating the inflammatory response and therefore represents one of the major advance in the field of inflammation.The International Congress on ... Read More »
» Published in Clin Exp Rheumatol. 2009 Mar-Apr;27(2):354-65.
10. Interleukin-6 as a therapeutic target in candidate inflammatory diseases.
Match Strength: 2.904
Interleukin (IL)-6 is a multifunctional cytokine that regulates immune response, inflammation, and hematopoiesis. Although IL-6 plays several important physiological roles, deregulated overproduction of IL-6 causes various clinical symptoms and abnormalities in laboratory test results. Overproduction of IL-6 has been shown to underlie a number of autoimmune and inflammatory diseases, including rheumatoid arthritis (RA), systemic-onset juvenile idiopathic arthritis (soJIA), and Castleman's disease, as well as malignancies such as multiple myeloma and mesothelioma. Blocking of IL-6 signaling may ... Read More »
» Published in Clin Pharmacol Ther. 2010 Apr;87(4):483-7. Epub 2010 Feb 24.
11. Nasal Wegener's and skin sarcoid--a rare combination of two granulomatous diseases.
Match Strength: 2.901
Wegener's granulomatosis (WG) and sarcoidosis are two distinct granulomatous diseases characterized by multisystem involvement. We report a patient who initially presented with symptoms of limited WG predominantly affecting the nose, followed by a facial rash, which was histologically proven to be due to sarcoidosis. The sequential development of these two diseases in one patient is very rare, and to our knowledge, only one such case has been reported in the last 50 years (Am J Kidney Dis 28:893-898, 1996) ... Read More »
» Published in Clin Rheumatol. 2006 Nov;25(6):895-7. Epub 2005 Nov 10.
12. The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody.
Match Strength: 2.856
Interleukin (IL)-6 plays essential roles not only in the immune response, but also in haematopoiesis and the central nervous system. Deregulated production of IL-6 has been found in chronic inflammatory autoimmune diseases, such as rheumatoid arthritis (RA), systemic onset juvenile idiopathic arthritis (soJIA), Crohn's disease (CD) and systemic lupus erythematosus (SLE). Furthermore, IL-6 activities can explain many symptoms of these diseases. More importantly, serum levels of IL-6 are correlated with disease activity. Based on these facts, the authors planned to develop a humanized anti-IL-6 ... Read More »
» Published in Expert Opin Biol Ther. 2005 May;5(5):683-90.
13. The Relationship between Parkin and Protein Aggregation in Neurodegenerative Diseases.
Match Strength: 2.853
The most prominent changes in neurodegenerative diseases are protein accumulation and inclusion formation. Several neurodegenerative diseases, including Alzheimer's, the Synucleinopathies and Tauopathies share several overlapping clinical symptoms manifest in Parkinsonism, cognitive decline and dementia. As degeneration progresses in the disease process, clinical symptoms suggest convergent pathological pathways. Biochemically, protein cleavage, ubiquitination and phosphorylation seem to play fundamental roles in protein aggregation, inclusion formation and inflammatory responses. In the ... Read More »
» Published in Front Psychiatr. 2010 Jun 3;1:15.
14. Inflammatory bowel disease: past, present, and future.
Match Strength: 2.853
Crohn's disease and ulcerative colitis, collectively known as the inflammatory bowel diseases (IBD), are largely diseases of the twentieth century, and are associated with the rise of modern, Westernized industrial society. Although the causes of these diseases remain incompletely understood, the prevailing model is that the intestinal flora drives an unmitigated intestinal immune response and inflammation in the genetically susceptible host. A review of the past and present of these diseases shows that detailed description preceded more fundamental elucidation of the disease processes. ... Read More »
» Published in J Gastroenterol. 2007 Jan;42(1):16-25. Epub 2007 Feb 16.
15. Risk factors of abdominal surgery in patients with collagen diseases.
Match Strength: 2.853
Patients with collagen diseases have been reported to demonstrate a greater risk when undergoing surgical operations. To determine the risk factors in abdominal surgery for patients with collagen diseases, 32 patients with collagen diseases who underwent abdominal surgery were analyzed for their clinical features and surgical results by comparing 26 cases from the favorable prognosis group (Group A) and 6 cases resulting in hospital death (Group B). The analysis revealed that emergent operations tended to result in worse outcomes (P = 0.011) than elective operations and that cases undergoing ... Read More »
» Published in Am Surg. 2006 Sep;72(9):843-8.
16. New aspect of anti-inflammatory action of lipo-prostaglandinE1 in the management of collagen diseases-related skin ulcer.
Match Strength: 2.845
It is considered that the mechanism in intractable cutaneous ulcer is deeply associated with prolongation at the inflammatory phase. Having evaluated the effects of Lipo-prostaglandin E1 (Lipo-PGE1) with indicators such as the reduction ratio of the ulcer area and the values of the inflammatory markers after dividing them into two groups of collagen diseases and non-collagen diseases and giving them Lipo-PGE1, we managed to obtain the result that Lipo-PGE1 administration could influence various inflammatory markers such as C-reactive protein (CRP), IL-6, and VEGF in addition to reduction of ... Read More »
» Published in Rheumatol Int. 2008 Sep;28(11):1127-35. Epub 2008 May 7.
17. Interstitial lung diseases: clinical features and management.
Match Strength: 2.839
Interstitial lung diseases (ILDs) or diffuse parenchymal lung diseases are terms used to describe around 200 acute and chronic lung disorders (Raghu and Brown, 2004). They are a heterogeneous group of disorders of the lower respiratory tract that are characterised by both acute and chronic inflammation and a generally irreversible and relentless process of fibrosis in the interstitium and the alveolar walls (air sacs in the lungs) (Riches et al, 2003) ... Read More »
» Published in Nurs Times. 2005 Jun 21-27;101(25):58-61.
18. Anticytokine therapy, particularly anti-IFN-gamma, in Th1-mediated autoimmune diseases.
Match Strength: 2.824
Anticytokine therapy was proposed in 1974 in Nature, in which it was stated that hyperproduced interferon can cause autoimmune disease and anti-interferon can be therapeutic. In 1989, the use of antibodies to tumor necrosis factor-alpha in combination with antibodies to certain types of interferon was proposed to treat various autoimmune diseases, including AIDS. The first anticytokine therapy was conducted in 1975. Anti-interferon-gamma has brought improved and often striking results in the treatment of various T-helper 1-mediated autoimmune diseases, including inflammatory skin diseases. ... Read More »
» Published in Expert Rev Clin Immunol. 2005 May;1(1):11-25.
19. Role of TNFalpha in pulmonary pathophysiology.
Match Strength: 2.813
Tumor necrosis factor alpha (TNFalpha) is the most widely studied pleiotropic cytokine of the TNF superfamily. In pathophysiological conditions, generation of TNFalpha at high levels leads to the development of inflammatory responses that are hallmarks of many diseases. Of the various pulmonary diseases, TNFalpha is implicated in asthma, chronic bronchitis (CB), chronic obstructive pulmonary disease (COPD), acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). In addition to its underlying role in the inflammatory events, there is increasing evidence for involvement of ... Read More »
» Published in Respir Res. 2006 Oct 11;7:125.
20. STAT3 in CD4+ T helper cell differentiation and inflammatory diseases.
Match Strength: 2.792
Jak/STAT pathways influence cell-fate decisions made by differentiating na�ve T cells, regulate the intensity and duration of inflammatory responses and are implicated in pathogenic mechanisms of a number of chronic inflammatory diseases. Among the STATs, the STAT3 protein has emerged as an important determinant of whether the na�ve T cell differentiates into regulatory (Treg) or an inflammatory (Th17) T cell lineage. STAT3 also has potent anti-inflammatory effects and regulates critical cellular processes such as, cell growth, apoptosis and transcription of inflammatory genes. Dysregulation ... Read More »
» Published in Cytokine. 2009 Sep;47(3):149-56. Epub 2009 Aug 3.
|<< Prev 20 ||Showing results 1 to 20 of 5,117||Next 20 >>|
* All information on Level1Diet.com is for educational purposes only. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Before changing your diet, or adding supplements to your diet, or beginning an exercise program, everyone should consult a qualified and licensed health practitioner; a physician, dietician or similar professional.